19730-99-5

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2-(PYRIDIN-3-YL)ACETIC ACID HYDRAZIDE is used as a building block for the synthesis of various pharmaceuticals and agrochemicals due to its versatile chemical properties and potential for creating new compounds with therapeutic or pesticidal effects.
Used in Drug Discovery Research:
2-(PYRIDIN-3-YL)ACETIC ACID HYDRAZIDE is used as a ligand in metal coordination chemistry for the development of new metal complexes with potential applications in medicinal chemistry.
Used in Antitumor and Antiviral Applications:
2-(PYRIDIN-3-YL)ACETIC ACID HYDRAZIDE is being investigated for its potential as an antitumor and antiviral agent, making it a promising candidate for the development of new therapeutic agents in oncology and virology.
Used in Antimicrobial Applications:
2-(PYRIDIN-3-YL)ACETIC ACID HYDRAZIDE has been examined for its potential to inhibit the growth of certain types of bacteria and fungi, making it of interest for applications in the development of new antimicrobial agents to combat drug-resistant infections.

InChI:InChI=1/C7H9N3O/c8-10-7(11)4-6-2-1-3-9-5-6/h1-3,5H,4,8H2,(H,10,11)

Upstream product

• 39998-25-9 methyl pyridine-3-acetate 
• 100-55-0 3-hydroxymethylpyridin 
• 6959-48-4 3-chloromethylpyridinium chloride 
• 6443-85-2 3-pyridinylacetonitrile 
• 39931-77-6 pyridin-3-yl-acetic acid ethyl ester 
• 501-81-5 pyridyl-3-yl-acetic acid 

Downstream Products

• 173599-04-7 3-pyridylacetylbenzamidrazone 
• 83417-25-8 3-amino-5-(3-pyridylmethyl)-1,2,4-triazole 
• 173598-96-4 3⁽⁵⁾-(1-butyl-3-pyridiniomethyl)-5⁽³⁾-phenyl-1,2,4-triazolate 
• 173599-00-3 3⁽⁵⁾-phenyl-5⁽³⁾-(3-pyridylmethyl)-1,2,4-triazole 

Relevant academic research and scientific papers

Dynamic Combinatorial Chemistry to Identify Binders of ThiT, an S-Component of the Energy-Coupling Factor Transporter for Thiamine

We applied dynamic combinatorial chemistry (DCC) to identify ligands of ThiT, the S-component of the energy-coupling factor (ECF) transporter for thiamine in Lactococcus lactis. We used a pre-equilibrated dynamic combinatorial library (DCL) and saturation-transfer difference (STD) NMR spectroscopy to identify ligands of ThiT. This is the first report in which DCC is used for fragment growing to an ill-defined pocket, and one of the first reports for its application with an integral membrane protein as target.

Tetrazolylhydrazides as selective fragment-like inhibitors of the JumonjiC-domain-containing histone demethylase KDM4A

The JumonjiC-domain-containing histone demethylase 2A (JMJD2A, KDM4A) is a key player in the epigenetic regulation of gene expression. Previous publications have shown that both elevated and lowered enzyme levels are associated with certain types of cancer, and therefore the definite role of KDM4A in oncogenesis remains elusive. To identify a novel molecular starting point with favorable physicochemical properties for the investigation of the physiological role of KDM4A, we screened a number of molecules bearing an iron-chelating moiety by using two independent assays. In this way, we were able to identify 2-(1H-tetrazol-5-yl)acetohydrazide as a novel fragment-like lead structure with low relative molecular mass (Mr=142 Da), low complexity, and an IC50 value of 46.6 μm in a formaldehyde dehydrogenase (FDH)-coupled assay and 2.4 μm in an antibody-based assay. Despite its small size, relative selectivity against two other demethylases could be demonstrated for this compound. This is the first example of a tetrazole group as a warhead in JMJD demethylases. Anchor fragment: To develop non-promiscuous metalloenzyme inhibitors, a metal-complexing acetohydrazide group was integrated in a tetrazolyl fragment, which can be matured into a scaffold to promote further selectivity at the ligand backbone binding site of these emerging drug targets.

Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine]

Cyclization of the benzoylpiperidine in lead compound 2 generated a series of novel and highly potent spiropiperidine-based stearoyl-CoA desaturase (SCD)-1 inhibitors. Among them, 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4′-piperidine] (19) demonstrated the most powerful inhibitory activity against SCD-1, not only in vitro but also in vivo (C57BL/6 J mice). With regard to the pharmacological evaluation, 19 showed powerful reduction of the desaturation index in the plasma of C57BL/6 J mice on a non-fat diet after a 7-day oral administration (q.d.) without causing notable abnormalities in the eyes or skin up to the highest dose (3 mg/kg) in our preliminary analysis.

Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3, 4-dihydrospiro[chromene-2,4′-piperidine] analogs

In continuation of our investigation on novel stearoyl-CoA desaturase (SCD) 1 inhibitors, we have already reported on the structural modification of the benzoylpiperidines that led to a series of novel and highly potent spiropiperidine-based SCD1 inhibitors. In this report, we would like to extend the scope of our previous investigation and disclose details of the synthesis, SAR, ADME, PK, and pharmacological evaluation of the spiropiperidines with high potency for SCD1 inhibition. Our current efforts have culminated in the identification of 5-fluoro-1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol- 2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4′-piperidine] (10e), which demonstrated a very strong potency for liver SCD1 inhibition (ID 50 = 0.6 mg/kg). This highly efficacious inhibition is presumed to be the result of a combination of strong enzymatic inhibitory activity (IC 50 (mouse) = 2 nM) and good oral bioavailability (F >95%). Pharmacological evaluation of 10e has demonstrated potent, dose-dependent reduction of the plasma desaturation index in C57BL/6J mice on a high carbohydrate diet after a 7-day oral administration (q.d.). In addition, it did not cause any noticeable skin abnormalities up to the highest dose (10 mg/kg).

NAPHTHYRIDINE INTEGRASE INHIBITORS

The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

Heterocyclic Amplifiers of Phleomycin. VIII Mono- and Bis-(5'-substituted 1',3',4'-thiadiazol-2'-yl)pyridines and Mono(5'-substituted 1',3',4'-thiadiazol-2'-ylmethyl)pyridines

A series of mono- and bis-(5'-substituted 1',3',4'-thiadiazol-2'-yl)pyridines with strongly basic side chains, e.g., 3,5-bispyridine (1), and (5'-substituted 1',3',4'-thiadiazol-2'-ylmethyl)pyridines have been prepared for evaluation as amplifiers of phleomycin.Five of this six bis(5'-substituted 1',3',4'-thiadiazol-2'-yl)pyridines were themselves antibacterial under the test conditions, but compounds (1) and the mono (5'-substituted 1',3',4'-thiadiazol-2'-yl)-pyridines and -methylpyridines displayed moderate two-to-three-star activity.